Neuphoria Therapeutics (BNOXN) Stock Statistics & Valuation Metrics

Neuphoria Therapeutics has a market cap or net worth of $343.96M. The enterprise value is ―.

Neuphoria Therapeutics has 5,404,551 shares outstanding. The number of shares has decreased by -2.65% in one year.

Neuphoria Therapeutics’s return on equity (ROE) is -0.01 and return on invested capital (ROIC) is -1.34%.

The current PE Ratio of Neuphoria Therapeutics is ―. Neuphoria Therapeutics’s PEG ratio is -0.24.

In the last 12 months, Neuphoria Therapeutics had revenue of 15.65M and earned -369.63K in profits. Earnings per share was -0.23.

In the last 12 months, operating cash flow was 59.46M and capital expenditures -3.00, giving a free cash flow of 59.46M billion.

Neuphoria Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Neuphoria Therapeutics upcoming earnings date is ―, ―.

Neuphoria Therapeutics as a current ratio of 3.56, with Debt / Equity ratio of 0.12%

In the past 12 months, Neuphoria Therapeutics has paid -468.37K in taxes.

Neuphoria Therapeutics EV to EBITDA ratio is 80.75, with an EV/FCF ratio of -0.13.

Neuphoria Therapeutics has $19.44M in cash and marketable securities with $34.23K in debt, giving a net cash position of $19.41M billion.

Gross margin is 104.75%, with operating margin of -7.21%, and net profit margin of -2.36%.

The average price target for Neuphoria Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―